Trial of Pfizer's lung cancer drug produces positive results

06/6/2010 | Reuters

Pfizer's experimental drug crizotinib reduced tumors in a majority of patients with advanced nonsmall-cell lung cancer who possess a specific genetic abnormality, U.S. researchers reported. Crizotinib inhibits a mutation that produces the carcinogenic gene EML4-ALK.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD